Product Description
We continuously develop and expand our robust pipeline of next-generation ADCs with innovative proprietary warheads. Current pipeline covers classic ADCs, bispecific ADCs, and bifunctional ADCs. These products, aiming to be the first-in-class or the best-in-class drugs, are currently at different stages of drug development. (Sourced from: https://www.bionecure.com/pipeline/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: BiOne Cure Therapeutics
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|